Radioimmunotherapy for prostate cancer - Current status and future possibilities

Seminars in Nuclear Medicine

Volumn 46, Issue 2, 2016, Pages 165-179

  Evans Axelsson, Susan ^a   Timmermand, Oskar Vilhelmsson ^b   Bjartell, Anders ^a   Strand, Sven Erik ^b   Elgqvist, Jörgen ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IODINE 131; LUTETIUM 177; PEPTIDE; RADIOISOTOPE; RHENIUM 188; YTTRIUM 90;

ARTICLE; AUGER ELECTRON SPECTROSCOPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; DOSIMETRY; EUROPE; HUMAN; MALE; METASTASIS; MOLECULARLY TARGETED THERAPY; MOLECULE; MULTIMODALITY CANCER THERAPY; NON PROFIT ORGANIZATION; NONHUMAN; PROSTATE CANCER; RADIOIMMUNOTHERAPY; SKIN CANCER; TREATMENT PLANNING; TUMOR MICROENVIRONMENT; UNITED STATES; ANIMAL; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS;

ANIMALS; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS; RADIOIMMUNOTHERAPY;

EID: 84958742902     PISSN: 00012998     EISSN: 15584623     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2015.10.005     Document Type: Review

References (212)

1. K. Strebhardt, and A. Ullrich Paul Ehrlich's magic bullet concept: 100 Years of progress Nat Rev Cancer 8 2008 473 480
2. D. Pressman, and L. Korngold The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies Cancer 6 1953 619 623
3. S.E. Order, G.B. Stillwagon, J.L. Klein, and et al. Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group study J Clin Oncol 3 1985 1573 1582
4. D.M. Goldenberg, F. DeLand, E. Kim, and et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning N Engl J Med 298 1978 1384 1386
5. G. Kohler, and C. Milstein Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 1975 495 497
6. S. DeNardo, K. Erickson, and E. Benjamin Use of I-131 antibodies for radiation therapy Clin Nucl Med 5 1980 S4 S5
7. S. DeNardo, K. Erickson, and E. Benjamin Radioimmunotherapy of melanoma Clin Cancer Res 29 1981 434A [Abstract]
8. J.A. Carrasquillo, K.A. Krohn, P. Beaumier, and et al. Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments Cancer Treat Rep 68 1984 317 328
9. L. Riechmann, M. Clark, H. Waldmann, and et al. Reshaping human antibodies for therapy Nature 332 1988 323 327
10. M. Verhoeyen, and L. Riechmann Engineering of antibodies Bioessays 8 1988 74 78
11. C. Queen, W.P. Schneider, H.E. Selick, and et al. A humanized antibody that binds to the interleukin 2 receptor Proc Natl Acad Sci U S A 86 1989 10029 10033
12. C. Aktolun, and S.J. Goldsmith Nuclear Medicine Therapy: Principles and Clinical Applications ed 1 2013 Springer New York
13. M.M. Schmidt, and K.D. Wittrup A modeling analysis of the effects of molecular size and binding affinity on tumor targeting Mol Cancer Ther 8 2009 2861 2871
14. M. Tomblyn, R. Elstrom, and A. Himelstein Novel combination of anti-CD22 radioimmunotherapy and anti-CD20 immunotherapy targeting two different antigens in non-Hodgkin lymphoma (NHL): Initial clinical experience J Nucl Med 2012 53 [Abstract 500]
15. M.B. Tomblyn, M.J. Katin, and P.E. Wallner The new golden era for radioimmunotherapy: Not just for lymphomas anymore Cancer Control 20 2013 60 71
16. P.M. Smith-Jones Radioimmunotherapy of prostate cancer Q J Nucl Med Mol Imaging 48 2004 297 304
17. D.M. Goldenberg Targeted therapy of cancer with radiolabeled antibodies J Nucl Med 43 2002 693 713
18. M. Tomblyn Radioimmunotherapy for B-cell non-hodgkin lymphomas Cancer Control 19 2012 196 203
19. R.M. Sharkey, and D.M. Goldenberg Cancer radioimmunotherapy Immunotherapy 3 2011 349 370
20. Wilkins LW, (ed): Targeted radionuclide therapy. (ed 1) Philadelphia, PA, Lippincott Williams & Wilkins, 2011
21. S. Nilsson, L. Franzen, C. Parker, and et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: A randomised, multicentre, placebo-controlled phase II study Lancet Oncol 8 2007 587 594
22. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
23. N. Vapiwala, and E. Glatstein Fighting prostate cancer with radium-223 - not your Madame's isotope N Engl J Med 369 2013 276 278
24. K. Lassi, and N.A. Dawson Emerging therapies in castrate-resistant prostate cancer Curr Opin Oncol 21 2009 260 265
25. L. Zarour, and J. Alumkal Emerging therapies in castrate-resistant prostate cancer Curr Urol Rep 11 2010 152 158
26. A. Heidenreich, D. Pfister, A. Marseburger, and et al. Castration-resistant prostate cancer: Where we stand in 2013 and what urologists should know Eur Urol 64 2013 260 265
27. I.F. Tannock, R. de Wit, W.R. Berry, and et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512
28. D.P. Petrylak, C.M. Tangen, M.H. Hussain, and et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520
29. P.W. Kantoff, S. Halabi, M. Conaway, and et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study J Clin Oncol 17 1999 2506 2513
30. I.F. Tannock, D. Osoba, M.R. Stockler, and et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points J Clin Oncol 14 1996 1756 1764
31. S.T. Tagawa, J.R. Osborne, S. Vallabahajosula, and et al. Prostate Specific Membrane Antigen-Based Therapeutics in Prostate cancer: A Comprehensive Perspective 2013 Springer New York
32. K. Bouchelouche, S.T. Tagawa, S.J. Goldsmith, and et al. PET/CT imaging and radioimmunotherapy of prostate cancer Semin Nucl Med 41 2011 29 44
33. K. Bouchelouche, P.L. Choyke, and J. Capala Prostate specific membrane antigen: A target for imaging and therapy with radionuclides Discov Med 9 2010 55 61
34. K. Bouchelouche, and J. Capala 'Image and treat': An individualized approach to urological tumors Curr Opin Oncol 22 2010 274 280
35. 90Y-CYT-356 monoclonal antibody Clin Cancer Res 2 1996 1289 1297
36. S.J. DeNardo, C.M. Richman, H. Albrecht, and et al. Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer Clin Cancer Res 11 2005 7187s 7194ss
37. 90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy Cancer Biother Radiopharm 14 1999 99 111
38. R.F. Meredith, A.J. Bueschen, M.B. Khazaeli, and et al. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49 J Nucl Med 35 1994 1017 1022
39. M.I. Milowsky, D.M. Nanus, L. Kostakoglu, and et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors J Clin Oncol 25 2007 540 547
40. 90yttrium-DOTA-peptide-ChL6 Prostate 50 2002 27 37
41. 90Y-2IT-BAD-m170 for metastatic prostate cancer Clin Cancer Res 7 2001 1561 1568
42. C.M. Richman, S.J. Denardo, R.T. O'Donnell, and et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody Clin Cancer Res 11 2005 5920 5927
43. S.T. Tagawa, H. Beltran, S. Vallabhajosula, and et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer Cancer 116 2010 1075 1083
44. 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice J Nucl Med 50 2009 435 443
45. 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy Clin Cancer Res 13 2007 5604s 5612ss
46. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer J Clin Oncol 23 2005 4591 4601
47. M.I. Milowsky, D.M. Nanus, L. Kostakoglu, and et al. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer J Clin Oncol 22 2004 2522 2531
48. R.E. Reiter, Z. Gu, T. Watabe, and et al. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer Proc Natl Acad Sci U S A 95 1998 1735 1740
49. Z. Gu, G. Thomas, J. Yamashiro, and et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer Oncogene 19 2000 1288 1296
50. H.W. Lue, X. Yang, R. Wang, and et al. LIV-1 promotes prostate cancer epithelial-to-mesenchymal transition and metastasis through HB-EGF shedding and EGFR-mediated ERK signaling PLoS One 6 2011 e27720
51. S. Evans-Axelsson, D. Ulmert, A. Orbom, and et al. Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone Cancer Biother Radiopharm 27 2012 243 251
52. J.K. Troyer, M.L. Beckett, and G.L. Wright Jr Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids Int J Cancer 62 1995 552 558
53. J.S. Horoszewicz, E. Kawinski, and G.P. Murphy Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients Anticancer Res 7 1987 927 935
54. R.L. Sokoloff, K.C. Norton, C.L. Gasior, and et al. A dual-monoclonal sandwich assay for prostate-specific membrane antigen: Levels in tissues, seminal fluid and urine Prostate 43 2000 150 157
55. R.S. Israeli, C.T. Powell, J.G. Corr, and et al. Expression of the prostate-specific membrane antigen Cancer Res 54 1994 1807 1811
56. R.S. Israeli, C.T. Powell, W.R. Fair, and et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen Cancer Res 53 1993 227 230
57. S.T. Tagawa, M.I. Milowsky, M. Morris, and et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer Clin Cancer Res 19 2013 5182 5191
58. 111indium-labeled monoclonal antibody PAY 276 J Urol 137 1987 439 443
59. R.O. Dillman, J. Beauregard, K.P. Ryan, and et al. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies NCI Monogr 1987 33 36
60. 111In-labelled anti-PAP and anti-PSA monoclonal antibodies examined in nude mice with PC-82 human tumor xenografts In Vivo 5 1991 159 165
61. D. Ulmert, M.J. Evans, J.P. Holland, and et al. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen Cancer Discov 2 2012 320 327
62. L.J. Schedlich, B.H. Bennets, and B.J. Morris Primary structure of a human glandular kallikrein gene DNA 6 1987 429 437
63. M.G. Lawrence, J. Lai, and J.A. Clements Kallikreins on steroids: Structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus Endocr Rev 31 2010 407 446
64. C.Y. Young, P.E. Andrews, P.T. Montgomery, and et al. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein Biochemistry 31 1992 818 824
65. M.F. Darson, A. Pacelli, P. Roche, and et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: A novel prostate cancer marker Urology 49 1997 857 862
66. M.F. Darson, A. Pacelli, P. Roche, and et al. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases Urology 53 1999 939 944
67. H.G. Rittenhouse, J.A. Finlay, S.D. Mikolajczyk, and et al. Human kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate Crit Rev Clin Lab Sci 35 1998 275 368
68. 111In-radiolabelled monoclonal antibody, 11B6 EJNMMI Res 4 2014 51
69. Y. Shi, F.H. Brands, S. Chatterjee, and et al. Her-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease J Urol 166 2001 1514 1519
70. A.E. Malara, C. Fedele, L. Aloj, and et al. Effects of a human compact anti-ErbB2 antibody on prostate cancer Oncol Rep 28 2012 297 302
71. 177Lu-labeled humanized monoclonal antibody against human epidermal growth factor receptor 2, Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD, 2004.
72. D.B. Agus, P.A. Bunn Jr, W. Franklin, and et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer Semin Oncol 27 2000 53 63 [discussion 92-100]
73. G. Sgouros, and R.F. Hobbs Dosimetry for radiopharmaceutical therapy Semin Nucl Med 44 2014 172 178
74. K. Sjogreen, M. Ljungberg, K. Wingardh, and et al. The LundADose method for planar image activity quantification and absorbed-dose assessment in radionuclide therapy Cancer Biother Radiopharm 20 2005 92 97
75. R.L. Siegel, K.D. Miller, and A. Jemal Cancer statistics, 2015 CA Cancer J Clin 65 2015 5 29
76. R.M. Hoffman, M.P. Couper, B.J. Zikmund-Fisher, and et al. Prostate cancer screening decisions: Results from the National Survey of Medical Decisions (DECISIONS study) Arch Intern Med 169 2009 1611 1618
77. A. Bill-Axelson, and O. Bratt Words of wisdom. Re: Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Eur Urol 67 2015 175
78. A. Heidenreich, P.J. Bastian, J. Bellmunt, and et al. EAU guidelines on prostate cancer. part 1: Screening, diagnosis, and local treatment with curative intent - update 2013 Eur Urol 65 2014 124 137
79. S.P. Kim, R.J. Karnes, P.L. Nguyen, and et al. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer BJU Int 113 2014 E106 E111
80. S. Loeb Prostate cancer screening: Highlights from the 29th European Association of Urology Congress Stockholm, Sweden, April 11-15, 2014 Rev Urol 16 2014 90 91
81. F.H. Schroder Screening for prostate cancer: Current status of ERSPC and screening-related issues Recent Results Cancer Res 202 2014 47 51
82. F.H. Schroder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
83. F.H. Schroder ERSPC, PLCO studies and critique of cochrane review 2013 Recent Results Cancer Res 202 2014 59 63
84. N. Mottet, J.B.E. Briers, D. van den Berg, and et al. Guidelines on prostate cancer Eur Urol 2015
85. NCCN: NCCN Guidelines on Prostate Cancer (version 1.2015). 2015:9-18 Available at: http://www.nccn.org. Accessed October 15, 2015
86. S. Edge, D.R. Byrd, C.C. Compton, and et al. AJCC Cancer Staging 2010 ManualSpringer-Verlag New York
87. T. Powles, I. Murray, C. Brock, and et al. Molecular positron emission tomography and PET/CT imaging in urological malignancies Eur Urol 51 2007 1511 1520 [discussion 20-1]
88. B. Turkbey, P.A. Pinto, and P.L. Choyke Imaging techniques for prostate cancer: Implications for focal therapy Nat Rev Urol 6 2009 191 203
89. S. Jana, and M.D. Blaufox Nuclear medicine studies of the prostate, testes, and bladder Semin Nucl Med 36 2006 51 72
90. 18F-labeled choline as an oncologic tracer for positron emission tomography: Initial findings in prostate cancer Cancer Res 61 2001 110 117
91. 18F-fluorodeoxyglucose PET and MR imaging J Magn Reson Imaging 31 2010 1151 1156
92. M.J. Morris, T. Akhurst, I. Osman, and et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 59 2002 913 918
93. 18Ffluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy Clin Cancer Res 11 2005 4761 4769
94. 18F-fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: A prospective study of 210 patients BJU Int 110 2012 1666 1671
95. 11C-acetate PET/CT: Comparative analysis for imaging prostate cancer patients Eur J Nucl Med Mol Imaging 40 1 2013 S18 S27 (suppl)
96. G. Murphy, M. Haider, S. Ghai, and et al. The expanding role of MRI in prostate cancer AJR Am J Roentgenol 201 2013 1229 1238
97. 11C-choline PET/MR with PET/CT in patients with prostate cancer Eur J Nucl Med Mol Imaging 40 2013 1486 1499
98. 18F-choline PET/CT Eur J Nucl Med Mol Imaging 41 2014 79 88
99. 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions J Nucl Med 55 2014 191 197
100. T.H. Van der Kwast, and M.J. Roobol Defining the threshold for significant versus insignificant prostate cancer Nat Rev Urol 10 2013 473 482
101. E.W. Steyerberg, M.J. Roobol, M.W. Kattan, and et al. Prediction of indolent prostate cancer: Validation and updating of a prognostic nomogram J Urol 177 2007 107 112 [discussion 12]
102. J.I. Epstein, P.C. Walsh, M. Carmichael, and et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer J Am Med Assoc 271 1994 368 374
103. J.I. Epstein, D.W. Chan, L.J. Sokoll, and et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings J Urol 160 1998 2407 2411
104. P.J. Bastian, B.H. Carter, A. Bjartell, and et al. Insignificant prostate cancer and active surveillance: From definition to clinical implications Eur Urol 55 2009 1321 1330
105. A. Heidenreich, P.J. Bastian, J. Bellmunt, and et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer Eur Urol 65 2014 467 479
106. P. Pepe, F. Fraggetta, A. Galia, and et al. Preoperative findings, pathological stage PSA recurrence in men with prostate cancer incidentally detected at radical cystectomy: Our experience in 242 cases Int Urol Nephrol 46 2014 1325 1328
107. 18F-fluorodeoxyglucose-positron emission tomography J Urol 169 2003 1337 1340
108. 11C-choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy Urol Int 84 2010 418 423
109. 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy Ann Nucl Med 24 2010 485 492
110. 18F-fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients Eur J Nucl Med Mol Imaging 33 2006 1387 1398
111. T. Ibrahim, E. Flamini, L. Mercatali, and et al. Pathogenesis of osteoblastic bone metastases from prostate cancer Cancer 116 2010 1406 1418
112. V. Helyar, H.K. Mohan, T. Barwick, and et al. The added value of multislice SPECT/CT in patients with equivocal bony metastasis from carcinoma of the prostate Eur J Nucl Med Mol Imaging 37 2010 706 713
113. J.A. O'Donoghue, M. Bardies, and T.E. Wheldon Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides J Nucl Med 36 1995 1902 1999
114. J. Elgqvist, S. Frost, J.P. Pouget, and et al. The potential and hurdles of targeted alpha therapy - Clinical trials and beyond Front Oncol 3 2014 324
115. N. Falzone, J.M. Fernandez-Varea, G. Flux, and et al. Monte Carlo evaluation of Auger electron-emitting theranostic radionuclides J Nucl Med 56 2015 1441 1446
116. A.D. Wrixon New ICRP recommendations J Radiol Prot 28 2008 161 168
117. ICRP Recommendations of the International Commission on Radiological Protection. ICRP publication Ann ICRP 37 2007 2 4
118. D.E. Troutner Chemical and physical properties of radionuclides Int J Rad Appl Instrum B 14 1987 171 176
119. B.W. Wessels, and C.F. Meares Physical and chemical properties of radionuclide therapy Semin Radiat Oncol 10 2000 115 122
120. A.I. Kassis, and S.J. Adelstein Radiobiologic principles in radionuclide therapy J Nucl Med 46 1 2005 4S 12S (suppl)
121. C.A. Hoefnagel Radionuclide therapy revisited Eur J Nucl Med 18 1991 408 431
122. P.B. Zanzonico Radiation dosimetry for targeted radionuclide therapy T.W. Speer, Targeted Radionuclide Therapy 2011 Lippincott Williams & Wilkins Philadelphia 108 128
123. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy J Nucl Med 51 2010 1974 1978
124. 90Y J Nucl Med 56 2015 1285 1291
125. P. Hoskin, O. Sartor, J.M. O'Sullivan, and et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: A prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial Lancet Oncol 15 2014 1397 1406
126. O. Sartor, R. Coleman, S. Nilsson, and et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial Lancet Oncol 15 2014 738 746
127. B.J. Allen, C.Y. Huang, and R.A. Clarke Targeted alpha anticancer therapies: Update and future prospects Biologics 8 2014 255 267
128. S. Nilsson Alpha-emitter radium-223 in the management of solid tumors: Current status and future directions Am Soc Clin Oncol Educ Book 2014 e132 e139
129. 223Ra injected intravenously into mice: Histology, clinical chemistry and hematology In Vivo 20 2006 325 331
130. R.B. Wilder, G.L. DeNardo, and S.J. DeNardo Radioimmunotherapy: Recent results and future directions J Clin Oncol 14 1996 1383 1400
131. C.Y. Huang, B.M. Oborn, S. Guatelli, and et al. Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy Med Phys 39 2012 1282 1288
132. 201Tl-chloride Cancer Biother Radiopharm 19 2004 562 569
133. A. Delker, W.P. Fendler, C. Kratochwil, and et al. Dosimetry for Lu-DKFZ-PSMA-617: A new radiopharmaceutical for the treatment of metastatic prostate cancer Eur J Nucl Med Mol Imaging 2015 [Epub ahead of print]
134. A. Afshar-Oromieh, H. Hetzheim, C. Kratochwil, and et al. The novel theranostic PSMA-ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: Biodistribution in humans, radiation dosimetry and first evaluation of tumor lesions J Nucl Med 56 2015 1697 1705
135. 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer Clin Cancer Res 21 2015 5277 5285
136. 177Lu-labeled PSMA I&T: Optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies J Nucl Med 56 2015 1169 1176
137. 177Lu-DOTA-huJ591 anti prostate specific membrane antigen specific monoclonal antibody Curr Radiopharm 2015 [Epub ahead of print]
138. H. Liu, P. Moy, S. Kim, and et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium Cancer Res 57 1997 3629 3634
139. S.A. Rajasekaran, G. Anilkumar, E. Oshima, and et al. A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen Mol Biol Cell 14 2003 4835 4845
140. P.M. Smith-Jones, S. Vallabhajosula, V. Navarro, and et al. Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: Preclinical studies in nude mice bearing LNCaP human prostate tumor J Nucl Med 44 2003 610 617
141. T.A. Rege, and J.S. Hagood Thy-1 as a regulator of cell-cell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis FASEB J 20 2006 1045 1054
142. A. Treister, O. Sagi-Assif, M. Meer, and et al. Expression of Ly-6, a marker for highly malignant murine tumor cells, is regulated by growth conditions and stress Int J Cancer 77 1998 306 313
143. I.P. Witz Differential expression of genes by tumor cells of a low or a high malignancy phenotype: The case of murine and human Ly-6 proteins J Cell Biochem Suppl 34 2000 61 66
144. R. Eshel, A. Zanin, O. Sagi-Assif, and et al. The GPI-linked Ly-6 antigen E48 regulates expression levels of the FX enzyme and of E-selectin ligands on head and neck squamous carcinoma cells J Biol Chem 275 2000 12833 12840
145. D.C. Saffran, A.B. Raitano, R.S. Hubert, and et al. Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts Proc Natl Acad Sci U S A 98 2001 2658 2663
146. S. Yu, F. Feng, K. Wang, and et al. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer Eur J Med Res 18 2013 56
147. T. Olafsen, Z. Gu, M.A. Sherman, and et al. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody J Immunother 30 2007 396 405
148. R. Montironi, R. Mazzucchelli, F. Barbisan, and et al. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: Comparison with clinically detected androgen-dependent and androgen-independent cancer Hum Pathol 37 2006 1137 1144
149. A. Ziada, A. Barqawi, L.M. Glode, and et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial Prostate 60 2004 332 337
150. 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice Int J Oncol 40 2012 1881 1888
151. S.S. Chang, V.E. Reuter, W.D. Heston, and et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature Cancer Res 59 1999 3192 3198
152. J. Singh Jaggi, E. Henke, S.V. Seshan, and et al. Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization PLoS One 2 2007 e267
153. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: Preclinical assessment J Nucl Med 55 2014 1842 1848
154. S. Boutaleb, J.-P. Pouget, C. Hindorf, and et al. Impact of mouse model on preclinical dosimetry in targeted radionuclide therapy IEEE 2009 2076 2085
155. M.W. Konijnenberg, and M. de Jong Preclinical animal research on therapy dosimetry with dual isotopes Eur J Nucl Med Mol Imaging 38 1 2011 S19 S27 (suppl)
156. E. Larsson, M. Ljungberg, S.E. Strand, and et al. Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies Acta Oncol 50 2011 973 980
157. 90Y-BR96 mAbs Med Phys 39 2012 4434 4443
158. S.E. Strand, P. Zanzonico, and T.K. Johnson Pharmacokinetic modeling Med Phys 20 1993 515 527
159. A. Pluen, Y. Boucher, S. Ramanujan, and et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs subcutaneous tumors Proc Natl Acad Sci U S A 98 2001 4628 4633
160. W. van Osdol, K. Fujimori, and J.N. Weinstein An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "binding site barrier" Cancer Res 51 1991 4776 4784
161. B.D. Mann, M.B. Cohen, R.E. Saxton, and et al. Imaging of human tumor xenografts in nude mice with radiolabeled monoclonal antibodies. Limitations of specificity due to nonspecific uptake of antibody Cancer 54 1984 1318 1327
162. R. Nilsson, M. Garkavij, O. Linden, and et al. Extracorporeal Techniques for Improving Radioimmunotherapy of Disseminated Malignant Tumors T.W. Speer, Targeted Radiocuclide Therapy 2011 Lippincott Williams & Wilkins Philadelphia 209 219
163. C. Hindorf, O. Linden, L. Stenberg, and et al. Change in tumor-absorbed dose due to decrease in mass during fractionated radioimmunotherapy in lymphoma patients Clin Cancer Res 9 2003 4003s 4006ss
164. M.G. Steffen, O.C. Boerman, W.J. Oyen, and et al. Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: Implications for fractionated dose radioimmunothearpy Cancer Res 59 1999 1615 1619
165. G. DeNardo, J. Schlom, D. Buchsbaum, and et al. Rationales, evidence, and design considerations for fractionated radioimmunotherapy Cancer 94 2002 1332 1348
166. S. Shen, J. Duan, and R.F. Meredith Model prediction of treatment planning for dose-fractionated radioimmunotherapy Cancer 94 2002 1264 1269
167. J.A. O'Donoghue, G. Sgouros, C.R. Divgi, and et al. Single-dose versus fractionated radioimmunotherapy: Model comparisons for uniform tumor dosimetry J Nucl Med 41 2000 538 547
168. 131I-labeled monoclonal antibody CC49 Cancer Res 55 1995 5881s 5887ss
169. G. Glatting, M. Bardies, and M. Lassmann Treatment planning in molecular radiotherapy Z Med Phys 23 2013 262 269
170. J. Gustafsson, P. Nilsson, and K.S. Gleisner On the biologically effective dose (BED)-using convolution for calculating the effects of repair: II. Numerical considerations Phys Med Biol 58 2013 1529 1548
171. J. Gustafsson, P. Nilsson, and K.S. Gleisner On the biologically effective dose (BED)-using convolution for calculating the effects of repair: I. Analytical considerations Phys Med Biol 58 2013 1507 1527
172. 90Y-radiolabeled anti-lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model J Nucl Med 47 2006 716 725
173. J.K. Troyer, Q. Feng, M.L. Beckett, and et al. Biochemical characterization and mapping of the 7E11-C5.3 epitope of the prostate-specific membrane antigen Urol Oncol 1 1995 29 37
174. Cytogen: Summary for basis of approval 95-0041 (Capromab Pendetide). In: FDA 1995. pp 1-27 [Available at: http://www.fda.gov ]
175. A. Ghosh, and W.D. Heston Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer J Cell Biochem 91 2004 528 539
176. G.L. Wright Jr, B.M. Grob, C. Haley, and et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy Urology 48 1996 326 334
177. N.H. Bander, E.J. Trabulsi, L. Kostakoglu, and et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen J Urol 170 2003 1717 1721
178. 89Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy J Urol 191 2014 1439 1445
179. 213Bi-J591) for radioimmunotherapy of prostate cancer Cancer Res 60 2000 6095 6100
180. 177Lu-labeled J591 monoclonal antibodies: Effect of multiple treatments on myelotoxicity Clin Cancer Res 11 2005 7195s 7200ss
181. 90Y-labeled fully human anti-CEA antibody Cancer Biother Radiopharm 29 2014 70 76
182. R.M. Sharkey, H. Karacay, S.V. Govindan, and et al. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models Mol Cancer Ther 10 2011 1072 1081
183. H. Choy, F.F. Rodriguez, S. Koester, and et al. Investigation of taxol as a potential radiation sensitizer Cancer 71 1993 3774 3778
184. S.V. Govindan, G.L. Griffiths, H.J. Hansen, and et al. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies Technol Cancer Res Treat 4 2005 375 391
185. C.M. van Rij, S. Lutje, C. Frielink, and et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2x anti-HSG bispecific antibody Eur J Nucl Med Mol Imaging 40 2013 1377 1383
186. 90Y-IMP-288 alone and combined with gemcitabine J Nucl Med 50 2009 2008 2016
187. 177Lu-labeled peptide Cancer Biother Radiopharm 29 2014 323 329
188. J.B. Pasternack, J.D. Domogauer, A. Khullar, and et al. The advantage of antibody cocktails for targeted alpha therapy depends on specific activity J Nucl Med 55 2014 2012 2019
189. G.W. Barendsen Dose fractionation, dose rate and iso-effect relationships for normal tissue responses Int J Radiat Oncol Biol Phys 8 1982 1981 1997
190. Dearnaley D, Syndikus I, Mossop H, et al. 5 Year outcomes of a phase III randomised trial of conventional or hypofractionated high dose intensity modulated radiotherapy for prostate cancer (CRUK/06/016): Report from the CHHiP trial investigators group. Presented at 2015 European Cancer Congress, Vienna, Austria. 2015: pp 25-29.
191. D.E. Rathkopf, M.R. Smith, JS de Bono, and et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302) Eur Urol 66 2014 815 825
192. C.N. Sternberg, D. Castellano, G. Daugaard, and et al. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: Final analysis of a multicentre, open-label, early-access protocol trial Lancet Oncol 15 2014 1263 1268
193. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
194. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
195. C. Rousseau, F. Kraeber-Bodere, J. Barbet, and et al. Pretargeted radioimmunotherapy: Clinically more efficient than conventional radioimmunotherapy Eur J Nucl Med Mol Imaging 40 2013 1373 1376
196. C.H. Chang, R.M. Sharkey, E.A. Rossi, and et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies Mol Cancer Ther 1 2002 553 563
197. O.C. Boerman, F.G. van Schaijk, W.J. Oyen, and et al. Pretargeted radioimmunotherapy of cancer: Progress step by step J Nucl Med 44 2003 400 411
198. D.M. Goldenberg, R.M. Sharkey, G. Paganelli, and et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy J Clin Oncol 24 2006 823 834
199. K. Herrmann, C. Bluemel, M. Weineisen, and et al. Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy J Nucl Med 56 2015 855 861
200. 124I-labeled anti-PSCA A11 minibody J Nucl Med 55 2014 452 459
201. 177Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer J Nucl Med 47 2006 1144 1152
202. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression J Nucl Med 50 2009 2017 2024
203. R.T. O'Donnell, S.J. DeNardo, X.B. Shi, and et al. L6 monoclonal antibody binds prostate cancer Prostate 37 1998 91 97
204. G. Sgouros, J.C. Roeske, M.R. McDevitt, and et al. MIRD Pamphlet No. 22 (abridged): Radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy J Nucl Med 51 2010 311 328
205. Ziegler J.F.: SRIM Monte Carlo software. [Accessed October 5, 2015]; Available at: http://www.srim.org
206. ICRU: ICRU Report 16: Linear energy transfer. Bethesda, MD 1970
207. ICRU: ICRU Report 37, Stopping powers for electrons and positrons. Bethesda, MD 1984
208. ICRU: ICRU Report 49, Stopping power and ranges for protons and alpha particles. Bethesda, MD 1984
209. AAPM: AAPM Report 37, Auger electron dosimetry. College Park, MD; 1992
210. NIST: ESTAR and ASTAR databases. Available at: http://www.nist.gov. Accessed October 6, 2015
211. Center NND: MIRD and ENSDF databases. Available at: http://www.nndc.bnl.gov. Accessed October 6, 2015
212. K.F. Eckerman, and A. Endo MIRD: Radionuclide data and decay schemes J Nucl Med 50 2009 2091